Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports Q3 2024 Financial Results and Corporate Updates
Summary
Terns Pharmaceuticals, Inc. announced its financial results for the third quarter of 2024, reporting a net loss of $21.9 million, an increase in cash position to $372.8 million, and provided updates on its clinical pipeline. The company plans to initiate a Phase 2 clinical trial for its obesity treatment TERN-601 in early Q2 2025, with initial data expected in the second half of 2025. Interim data from the Phase 1 trial for its chronic myeloid leukemia treatment TERN-701 is expected in early December 2024.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement